Telix Pharmaceuticals Ltd
ASX:TLX

Watchlist Manager
Telix Pharmaceuticals Ltd Logo
Telix Pharmaceuticals Ltd
ASX:TLX
Watchlist
Price: 24.455 AUD -1.67% Market Closed
Market Cap: 8.2B AUD
Have any thoughts about
Telix Pharmaceuticals Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one TLX stock under the Base Case scenario is 26.17 AUD. Compared to the current market price of 24.455 AUD, Telix Pharmaceuticals Ltd is Undervalued by 7%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TLX Relative Value
Base Case
26.17 AUD
Undervaluation 7%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

12.7
P/S
P/S
Price to Sales
12.7
vs History
57
vs Industry
41
Median 3Y
13.4
Median 5Y
20.7
Industry
7.6
Forward
10.5
More Details
166.2
P/E
P/E
Price to Earnings
166.2
vs History
9
vs Industry
0
Median 3Y
-18.3
Median 5Y
-22.1
Industry
22.1
Forward
135
More Details
164.4
P/OCF
P/OCF
Price to OCF
164.4
vs History
26
vs Industry
0
Median 3Y
-16
Median 5Y
-16.3
Industry
21.9
More Details
314.8
P/FCFE
P/FCFE
Price to FCFE
314.8
vs History
20
vs Industry
0
Median 3Y
-14.3
Median 5Y
-15.3
Industry
23.4
More Details
20.2
P/B
P/B
Price to Book Value
20.2
vs History
52
vs Industry
1
Median 3Y
28
Median 5Y
21.1
Industry
2.5
More Details
12.5
EV/S
EV/S
Enterprise Value to Sales
12.5
vs History
57
vs Industry
35
Median 3Y
12.7
Median 5Y
20
Industry
7.5
Forward
10.4
More Details
20.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
20.2
vs History
57
vs Industry
26
Median 3Y
21.4
Median 5Y
33.7
Industry
9.3
More Details
109.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
109.6
vs History
9
vs Industry
0
Median 3Y
-17.8
Median 5Y
-24.2
Industry
4.2
Forward
69.5
More Details
109.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
109.6
vs History
9
vs Industry
0
Median 3Y
-17.8
Median 5Y
-24.2
Industry
4
Forward
79.5
More Details
162.4
EV/OCF
EV/OCF
Enterprise Value to OCF
162.4
vs History
25
vs Industry
0
Median 3Y
-14.6
Median 5Y
-15
Industry
5.9
More Details
378.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
378.9
vs History
22
vs Industry
0
Median 3Y
-13.2
Median 5Y
-14.7
Industry
3.9
More Details
13.3
EV/IC
EV/IC
Enterprise Value to IC
13.3
vs History
68
vs Industry
10
Median 3Y
18
Median 5Y
16.1
Industry
4.5
More Details

Multiples Across Competitors

TLX Competitors Multiples
Telix Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Telix Pharmaceuticals Ltd
ASX:TLX
8.2B AUD 12.7 166.2 109.6 109.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 027 714.7 -180 740.1 -219 476 -216 971.5
US
Abbvie Inc
NYSE:ABBV
310.3B USD 5.6 61.1 15.2 23.4
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 4.4 33.5 16 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 4.1 915.4 10.2 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 9.6 -213.4 21 22.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 852.6 -472.7 -514.8 -501.1
AU
CSL Ltd
ASX:CSL
134.4B AUD 5.7 31.8 19.7 24.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 5.6 16.6 15.1 16.7
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.7 -58.8 -53
NL
argenx SE
XBRU:ARGX
35.7B EUR 19.2 -134.7 -108.7 -79.2
P/S Multiple
Revenue Growth P/S to Growth
AU
Telix Pharmaceuticals Ltd
ASX:TLX
Average P/S: 3 457 241.1
12.7
167%
0.1
FR
Pharnext SCA
OTC:PNEXF
38 027 714.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
34%
0.3
US
E
Epizyme Inc
F:EPE
1 852.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.2
220%
0.1
P/E Multiple
Earnings Growth P/E to Growth
AU
Telix Pharmaceuticals Ltd
ASX:TLX
Average P/E: 204.1
166.2
3 638%
0
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.1
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
915.4
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -213.4
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.8
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -134.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Telix Pharmaceuticals Ltd
ASX:TLX
Average EV/EBITDA: 29.5
109.6
1 593%
0.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 476 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -108.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Telix Pharmaceuticals Ltd
ASX:TLX
Average EV/EBIT: 33.8
109.6
1 524%
0.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 971.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.6
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.2 N/A N/A

See Also

Summary
TLX intrinsic value, competitors valuation, and company profile.
DCF Valuation
TLX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TLX stock valuation using valuation multiples.
Wall Street Estimates
TLX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TLX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.